TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
In a randomized trial of 584 adults with septic shock undergoing surgical source control, adding dobutamine to norepinephrine was associated with lower acute kidney injury rates within seven days of surgery. Tachycardia was more frequent with dobutamine; the study found no statistically significant differences in several other outcomes, including mortality and kidney replacement therapy.
A randomized trial involving 584 adults with septic shock found that adding dobutamine to norepinephrine during surgery was associated with fewer cases of acute kidney injury (AKI) in the following seven days than norepinephrine alone. The findings, published in JAMA and presented at the European Society of Intensive Care Medicine annual congress, suggest a possible way to reduce kidney complications during surgical source control, but the authors described the results as hypothesis-generating.
New-onset or worsening AKI occurred within seven days in 22.8% of patients given the combination, compared with 34.7% receiving norepinephrine alone. The adjusted risk ratio was 0.64, with a 95% confidence interval of 0.49 to 0.83. The study was open-label and conducted at 39 tertiary hospitals in China. Participants had a median age of 67.5, and about one-third were women.
During surgery, patients assigned to dobutamine received a continuous infusion starting at 5 micrograms per kilogram per minute, alongside norepinephrine. In both groups, clinicians adjusted norepinephrine to target a mean arterial pressure of 65 mm Hg. Gastrointestinal perforation was the most common reason for surgery, affecting 41.8% of participants; gastrointestinal obstruction accounted for 29.6%.
Patients receiving the combination had a lower median SOFA score on the first postoperative day, five compared with six, and higher median urine output one hour after treatment began, 2.4 compared with 1.9 milliliters per kilogram per hour. These were among the reported findings; the researchers found no statistically significant difference in nine other secondary outcomes. Exploratory analyses also found fewer stage 2 and stage 3 AKI cases with dobutamine, but no difference in stage 1 AKI.
Kidney Complications After Source Control
AKI can add to the burden of critical illness for people already facing septic shock and emergency surgery. Surgical source control—an operation to address the infection’s cause—is a key part of treatment for some patients, but shock and the stress of surgery can impair tissue perfusion. The trial addresses a practical question for clinicians: whether adjusting drugs that support circulation during the operation might affect kidney outcomes afterward.
The size of the observed difference in seven-day AKI incidence makes the result relevant to intensive care and surgical teams, but it does not establish that the combination should become routine. The trial did not show statistically significant differences in mortality, need for kidney replacement therapy or hospital length of stay. Those findings mean the reported reduction in AKI has not yet been shown to translate into improved survival or shorter hospitalization.
The safety findings also warrant attention. Tachycardia occurred more often with dobutamine, in 41% of patients versus 29.9% with norepinephrine alone. The study reported comparable rates of serious cardiac adverse events and similar heart rates at the end of surgery, but those results do not remove the need to weigh heart-rate effects in individual patients.
intraoperative dobutamine infusion pump
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Why Researchers Tested Dobutamine
Norepinephrine is commonly used to support blood pressure in septic shock. The source report notes that its vasoconstricting effects may reduce regional kidney blood flow. Dobutamine can increase blood flow to the kidneys and glomerular filtration, but its role in preventing septic AKI has been debated; earlier observational studies had linked its use with AKI progression or kidney replacement therapy.
The researchers said there had not been an established intraoperative treatment specifically aimed at countering the combined effects of septic shock and surgical stress on tissue perfusion. They described their trial as the first large multicenter study specifically testing the addition of intraoperative dobutamine during surgical source control. The intervention was limited to the operation itself, and AKI was assessed over the next seven days.
“Timely source control with surgical intervention is a cornerstone of management in septic shock, necessary in 20% to 30% of patients, and associated with improved outcome.”
— The study authors
As an affiliate, we earn on qualifying purchases.
Limits of the Trial Findings
The results do not establish whether the lower AKI rate will be reproduced in other health systems or patient groups. The trial was conducted in China, was open-label and enrolled adults undergoing surgery for septic shock. The source report also identifies inconsistent use of advanced hemodynamic monitoring as a limitation, and the treatment was given only during the operation.
It remains unclear which patients, if any, benefit most, and whether the AKI difference leads to better longer-term kidney function or survival. The report says no statistically significant interactions were found across prespecified subgroups, so it does not identify a subgroup with a proven distinct response. Exploratory differences in more severe AKI stages also need further testing. The reported results do not establish a change to standard care.
hospital kidney injury monitoring devices
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Further Testing Across Patient Groups
The authors called the findings hypothesis-generating and said additional research could examine how responses to dobutamine vary across clinical subtypes. Further studies would need to test whether the reduction in seven-day AKI is reproducible, clarify which patients are most likely to benefit, and assess outcomes beyond the operation and first postoperative week.
The report does not specify a timetable for another trial or a change in clinical guidance. For now, the key next step is independent confirmation of the kidney outcome alongside careful tracking of tachycardia, serious cardiac events and longer-term patient outcomes.
As an affiliate, we earn on qualifying purchases.
Key Questions
What did the trial find?
Among adults with septic shock undergoing surgical source control, AKI within seven days occurred in 22.8% with dobutamine plus norepinephrine and 34.7% with norepinephrine alone. The reported adjusted risk ratio was 0.64.
How was dobutamine given?
Patients in the combination group received a continuous dobutamine infusion starting at 5 micrograms per kilogram per minute during surgery. Norepinephrine was used in both groups and titrated to a mean arterial pressure target of 65 mm Hg.
Did the combination reduce deaths or kidney replacement therapy?
The trial found no statistically significant differences in mortality or the need for kidney replacement therapy. The reported main finding was lower AKI incidence within seven days.
What side effect was more frequent?
Tachycardia was reported in 41% of patients receiving dobutamine, compared with 29.9% in the norepinephrine-only group. Serious cardiac adverse events were reported as comparable between groups.
Does this mean dobutamine should be used routinely during these operations?
No such conclusion is established by this study. The authors characterized the findings as hypothesis-generating, and further research is needed to confirm the result and clarify which patients may benefit.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
